Episodios
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss why measles remains a virus of concern, how avian flu continues to spread, and new developments in the federal regulation of laboratory-developed tests.
Their discussion includes:
How a person infected with measles recently traveled through a U.S. airport, and the severity of the measles virus.The continued deadly spread of avian flu among wild birds, domestic poultry, and cattle, and the infection of a third human.Avian flu vaccine development and the importance of emergency preparedness.The American Clinical Laboratory Association’s (ACLA) lawsuit against the U.S. Food and Drug Administration (FDA) regarding the agency’s final rule to treat laboratory-developed tests as medical devices. -
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 assays facilitate care for central nervous system disorders triggered by cancer. Early diagnosis and treatment are important for managing disabling neurological symptoms and malignancy.
(00:32)
Could you tell us a bit about your background and your role at Mayo Clinic?(01:26)
How do the tests that are coming live relate to the larger disease state of neurological disorders?(02:44)
Can you share a little bit about the methodology we're using for these particular biomarkers?(05:15)
How was PDE10A discovered?(06:48)
Anything you would add?(07:50)
Remind us which phenotype-specific assays these biomarkers are being added to, and how physicians should determine whether this testing is appropriate?(09:55)
What does early detection of these biomarkers mean for the patient's prognosis, diagnosis, treatment, etc.?(12:33)
What are you most excited about with the launch of these tests? -
¿Faltan episodios?
-
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Peter Lucas, M.D., Ph.D., vice chair of Research for the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.
Their discussion includes:
Dr. Lucas’ extensive pathology and research background and his journey to Mayo Clinic. His goals for expanding DLMP’s research activities and advancing innovation in diagnostics.How laboratory research has evolved over his career and how researchers can continue to make progress despite obstacles.The importance of having good mentors, collaborating with others, staying curious, and remaining persistent to achieve goals. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the widespread outbreaks of H5N1 bird flu and the new “FLiRT” variants of COVID-19.
Specific topics of discussion include:
The current situation of avian flu activity across the world and throughout the United States, including outbreaks in poultry, U.S. dairy cows, and one recent human case.How this outbreak is different than previous ones, and the current public health risk.Resources for testing humans for avian flu.What we know about the new “FLiRT” variants of COVID-19 and how they might impact public health in the months ahead. -
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
(00:31)
Can you tell us a little about yourself and your background — Beth?(01:24)
Stephanie, what about you?(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?
(04:02)
What changes did you incorporate into the test?(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?(07:12)
Does including these genes guide patient care in a more valuable way?(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?(10:27)
Is having many options available in a one-stop shop important to help guide patient management?(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care? -
Rapidly progressive dementia covers many conditions, including Creutzfeldt-Jacob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' new evaluations help identify the cause of rapidly progressive dementia, to guide prognosis and treatment decisions.
Show notes
Speaker 3: (00:32)
Can you provide a little background about your role here at Mayo Clinic and experience with this disease state?Speaker 3: (01:21)
Can you give us an understanding of rapidly progressive dementia? How is it different and what should physicians be looking for?Speaker 3: (03:13)
You mentioned "syndromic" and that there are several diseases underneath that, one of them being Creutzfeldt-Jacob. Can you explain the others in a bit more detail? What makes them each unique under the heading of rapidly progressive dementias?Speaker 3: (05:29)
Does that encompass it: prion diseases, then the neurodegenerative bucket, then autoimmune?Speaker 3: (06:03)
Can you speak to the components of the new Creutzfeldt-Jacob disease-specific evaluation and the rapidly progressive dementia evaluation, and the assays that they're performed on?Speaker 3: (09:30)
Anything you want to add to that summary of the assays' components?Speaker 3: (11:09)
Can you explain the role — or lack thereof — of the 14-3-3 protein biomarker, according to our research?Speaker 3: (13:44)
Which patients should get this testing, and who should not?Speaker 3: (17:22)
What does it mean if the results come back positive and if the results come back negative?Speaker 3: (21:57)
What are you most excited about with these tests? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Eric Hsi, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic.
Their discussion includes:
Dr. Hsi’s experience in the field of pathology and what he is looking forward to working on as the new chair of the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.Some common challenges facing laboratory professionals today and ways to overcome them.Advancements and trends in pathology and staying current with new developments.Words of advice for pathologists who are beginning their careers. -
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
(00:32)
Can you tell us a little bit about yourself and your background?(01:46)
Can you please provide an overview of laboratory testing for substance use disorders and specifically Mayo Clinic's new oral fluid controlled substance monitoring option?(03:47)
Which patients should have this testing and when should it be performed?(05:16)
What alternative test options are available and how do these compare?(06:31)
How are the results used in patient care? -
In this special episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the final rule issued by the U.S. Food and Drug Administration (FDA) on April 29, 2024, to make explicit its plan to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act.
Their discussion includes:
Highlighting key points, exceptions, and the phased implementation plan of the final rule.How the FDA’s final rule compares to its proposed rule from last year.How the news may impact laboratories, health systems, health agencies, and manufacturers.Uncertainties that still remain regarding the future of laboratory-developed tests. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Robin Patel, M.D.,director of the Infectious Diseases Research Laboratory and co-director of the Bacteriology Laboratory at Mayo Clinic. They discuss antimicrobial resistance and why it’s a major global health concern.
Specific topics of discussion include:
Background information on antimicrobial resistance and why it is a growing threat to global health.What is being done to address the problem, and Dr. Patel’s work as a member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria.How laboratorians and pathologists can advocate for continued action on antimicrobial resistance. -
David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.
(00:31)
Could you please provide a little bit about yourself and your background?(01:30)
Would you please share a brief overview of the UBA1Q assay?(02:13)
Would you provide an overview of VEXAS syndrome?(05:30)
When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?(06:38)
What advantage does this assay provide over other methodologies?(10:13)
Could you share further why diagnosis is so important for these patients?
(12:40)
Is there anything else you'd like to comment about the assay? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss testing innovations for Alzheimer’s disease and cognitive impairments, and how laboratorians can responsibly help shape the future of healthcare.
Their discussion includes:
The latest news about the U.S. Food and Drug Administration’s (FDA) proposed rule around regulating lab-developed tests.New testing innovations for Alzheimer’s disease and cognitive impairments, including Mayo Clinic Laboratories’ plasma biomarker testing for Alzheimer’s disease. The importance of being responsible lab stewards and working closely with clinicians to understand how different testing approaches drive decision-making in healthcare settings. -
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
(00:32)
Could you provide us with a little bit of information about yourself and your background?(01:18)
Can you start with a brief overview of the assay?(02:13)
Which patients should have this testing and when should it be performed?(03:21)
Are there alternative test options available and how do those compare with the folate receptor alpha assay?(03:57)
How are the results used in patient care? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including Medical Laboratory Professionals Week, recent healthcare conferences, advocacy efforts, measles, and bird flu.
Their discussion includes:
Key takeaways from the Becker’s Healthcare Annual Meeting and the College of American Pathologists’ (CAP) Pathologists Leadership Summit.The resurgence of measles cases and recent activity of bird flu (H5N1).Tips for staying engaged and being the voice for patients. -
Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.
(00:32)
Do you mind giving the audience more information about yourself and your background?(01:53)
Could you please give a brief overview of this assay?(03:35)
Which patients should have this testing and when should it be performed?(04:57)
How are the results used in patient care?(06:59)
Other monoclonal antibody therapies are usually monitored by a combination of drug quantification and analysis of antidrug antibodies. How is this test being offered? -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, to discuss tick-borne diseases and the latest testing options.
Specific topics of discussion include:
The types of tick-borne diseases found throughout the United States. Algorithmic approaches and testing methods used to diagnose tick-borne diseases.Helpful resources for clinicians, including Mayo Clinic Laboratories’ Acute Tickborne Disease Testing Algorithm and Lyme Neuroborreliosis Diagnostic Algorithm.New tests recently developed by Mayo Clinic Laboratories to aid in the diagnosis of tick-borne disease, including:A broad range bacterial PCR and sequencing test for tick-borne bacteria and some zoonotic bacterial pathogens that may have a similar presentation (Mayo ID: BRBST).Molecular PCR testing to detect the viral RNA of Heartland virus in spinal fluid (Mayo ID: HRTVC) and serum (Mayo ID: HRTVS).Preventing tick bites. -
Alicia Algeciras-Schimnich, Ph.D., discusses how Mayo Clinic Laboratories’ new noninvasive blood test for Alzheimer’s disease identifies the p-tau217 biomarker, which is associated with the accumulation of amyloid beta in the brain. Positive test results can facilitate access to disease-modifying therapies.
(00:32):
Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?
(01:45):So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes?
(07:39)
So can you explain a little bit more about what the results that our clients will receive look like?(10:30)
Can you just give a quick overview of how our test is unique compared to those on the market?(12:24)
What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well?(14:42)
Let's talk now about how those results are used in patient care.(16:31)
One more question, just summarize for our listeners what you're most excited about with this new test. -
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current events including dengue outbreaks, new colon cancer screening technology, and insurance coverage of innovative lab tests.
Their discussion includes:
The surge of dengue cases in Latin America, and best practices for tick and mosquito bite prevention.Advancements in laboratory tests and technology used for colon cancer screening.Issues with insurers paying for new screening technology versus routine screening methods.How laboratorians can help educate physicians and policymakers on how innovative laboratory tests create value for patients and the entire healthcare system. -
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
(00:33)
Do you mind giving us a brief introduction of yourself and what you do at Mayo?(01:45)
Can you tell us a little about the test and how it came to be?(03:00)
Could you explain the types of patients this test would be best suited for and how a provider might determine if their patient would benefit from this?(03:32)
Would you please explain why the algorithm is recommended and where in the algorithm this test fits?(04:36)
What makes this test different from what's currently available to providers?(05:38)
How can the information be used in patient care? And can you talk a little bit about how the diagnosis can be clarified by using this assay, why it's important, and how the results would impact a patient's care and treatment plan? -
The Centers for Disease Control and Prevention (CDC) issued a recent health advisory in response to the increasing number of measles outbreaks in the United States.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic, to discuss why measles is in the news again and how we can prevent measles outbreaks.
Specific topics of discussion include:
The symptoms, characteristics, and complications of the measles virus.The recent rise in measles cases and outbreaks being reported across the United States.The importance of vaccination in preventing the spread of the highly contagious virus.Why the measles laboratory test was eventually developed, and testing options available through Mayo Clinic Laboratories. - Mostrar más